Metabolic comorbidities are common in patients with cardiorenal disease; they can cause
atherosclerotic cardiovascular disease (ASCVD), speed progression, and adversely affect …

Steatotic liver disease (SLD) is a worldwide public health problem, causing considerable
morbidity and mortality. Patients with SLD are at increased risk for major adverse …

The alarming rise in obesity worldwide is a dramatic public health concern [1], and changes
in lifestyle factors, such as low physical activity and the progressive diffusion of the high …

Anti‐obesity medications act by suppressing energy intake (EI), promoting energy
expenditure (EE), or both. Metformin (Met) and mirabegron (Mir) cause weight loss by …

This is a cross-sectional study with women divided into a group of those with obesity (n= 80)
and a control group (n= 94). Statistical analysis was conducted using the SPSS program …

Abstract Purpose of Review Type 2 diabetes mellitus (T2DM) is a complex health issue
include obesity, high cholesterol, high blood pressure, and chronic inflammation that …

Evidence-based medicine shows that obesity is associated with a wide range of
cardiovascular (CV) diseases. Obesity can lead to changes in cardiac structure and function …

Truncal obesity is a key modifiable risk factor in cardiovascular disease (CVD). It is a highly
complex phenotype, and numerous factors such as the distribution of adipose tissue may …

A disfunção do tecido adiposo favorece alterações no metabolismo do cortisol, o que pode
contribuir para a hipozincemia, hiposelenemia e hipamagnesemia em indivíduos com …

A obesidade/sobrepeso é uma pandemia mundial, doença inflamatória crônica e
multifatorial que afeta pacientes de todas as idades e rendas em todo o mundo. As doenças …